Participating Companies

Aadi Bioscience
Based on the AM­PECT trial, emerg­ing da­ta for ABI-009 in other solid tu­mors with TSC1 or TSC2 mu­ta­tions, and fol­low­ing dis­cus­sions with the FDA, Aa­di is pro­ceed­ing with a tu­mor-ag­nos­tic reg­is­tra­tio­n­al trial in can­cers har­bor­ing TSC1 or TSC2 patho­genic, in­ac­ti­vat­ing mu­ta­tions with a planned ini­ti­a­tion in 2021. [more in­for­ma­tion]
AavantiBio, Inc.
Head­quar­tered in the greater Bos­ton area, Aa­vantiBio is co-found­ed by renowned gene ther­a­py re­search­ers Bar­ry Byrne, M.D. Byrne and Cor­ti in Frie­dreich’s Ataxia, among other rare ge­net­ic di­s­or­ders. Ini­tial fund­ing in Aa­vantiBio was pro­vid­ed by Go­FAR, an Italian pa­tient ad­vo­ca­cy group, and the Mus­cu­lar Dys­tro­phy As­so­ci­a­tion Ven­ture Phi­lan­thropy Fund. [more in­for­ma­tion]
Abbisko Therapeutics Co., Ltd.
The com­pany is found­ed by a group of sea­soned drug hun­ters with rich re­search and ma­n­age­ment ex­pe­ri­ence in both top in­ter­na­tio­n­al phar­ma­ceu­ti­cal com­pa­nies and Chi­nese in­dus­trial lead­ers. [more in­for­ma­tion]
Ability Pharmaceuticals, SL
ABTL0812 has been grant­ed Or­phan Drug Desig­na­tion (ODD) for neu­roblas­to­ma, pan­cre­at­ic can­cer and for biliary tract can­cer by FDA and EMA, and the drug has a sales po­ten­tial over &eu­ro;2.5 bil­lion in 2025, with a mar­ket share over 80% in se­lect­ed can­cer types. [more in­for­ma­tion]
Adrenomed AG
Pre­ci­sion medicine, car­dio­vas­cu­lar and Sep­sis, Adre­cizumab Ph 2, bio­mark­er-guid­ed, mon­o­clo­n­al anti­body for sep­tic shock; fi­nal da­ta re­leased late Novem­ber: Ear­ly ap­pli­ca­tion of Adre­cizumab leads to a rapid and sta­tis­ti­cal­ly sig­ni­f­i­cant im­prove­ment of fluid bal­ance, sys­temic or­gan func­tion and > 50% rel­a­tive re­duc­tion of all cause mor­tal­i­ty af­ter 28 days and 90 days com­pared to place­bo on top of SoC. [more in­for­ma­tion]
Pro­pri­e­tary Af­fi­body® molecules and Al­bu­mod plat­forms. Lead can­di­date is an IL-17 with pos­i­tive Ph2 52wk da­ta in pso­ri­a­sis and Ph2 IND for lead in­di­ca­tion uvei­tis will be filed in Q1 2021. In ad­di­tion, the com­pany has an on­go­ing re­la­tion­ship with In­ma­gene in Chi­na. Backed by In­ves­tor AB. [more in­for­ma­tion]
Akili Interactive Labs
Ak­ili is pi­oneer­ing the de­vel­op­ment of dig­i­tal treat­ments and care so­lu­tions to help peo­ple af­fect­ed by cog­ni­tive im­pair­ments. Ak­ili’s treat­ments are de­signed to di­rect­ly ac­ti­vate the net­works in the brain re­spon­si­ble for cog­ni­tive func­tion and have been ri­g­or­ous­ly test­ed in ex­ten­sive clin­i­cal studies, in­clud­ing prospec­tive ran­domized, con­trolled trials. [more in­for­ma­tion]
AM-Pharma B.V.
Re­sults from Ph 2 in 300+ pts de­mon­s­trat­ed im­prove­ment of 40%+ OS in re­cAP group. Ini­ti­at­ed Ph 3 in Q4 2020; TL safe­ty & fu­til­i­ty anal­y­sis on first 400 pts exp YE2021. Ex­pects to com­plete tgt en­roll­ment & an­nounce pri­mary end­point da­ta of 28-day all-cause mor­tal­i­ty in 2023. [more in­for­ma­tion]
Amakos Biotherapeutics, Inc.
Based on much of the pi­oneer­ing re­search from Pro­fes­sor Makriyan­nis it is known that en­do­cann­abi­noids act­ing in the pe­riph­ery are as­so­ci­at­ed with in­flam­ma­tion and fi­bro­sis in a num­ber of dis­eas­es. Dis­cov­ery of the pe­ripher­al­ly se­lec­tive neu­tral an­ta­g­on­ists of the CB-1 re­cep­tor opened the door to new and much safer ap­proach­es to treat lung, kid­ney, and liv­er fi­bro­sis. [more in­for­ma­tion]
Antios Therapeutics
An­tios Ther­a­peu­tics is a clin­i­cal-stage bio­phar­ma­ceu­ti­cal com­pany fo­cused on the de­vel­op­ment of in­no­va­tive ther­a­pies to treat and cure vi­ral dis­eas­es. Da­ta from the Phase 1b study in HVB-in­fect­ed pa­tients are ex­pect­ed to be re­port­ed in 2021.A Phase 2a study (both mono- and com­bi­na­tion ther­a­py) is ex­pect­ed to be ini­ti­at­ed lat­er in 2021. [more in­for­ma­tion]
Aristea Therapeutics
Aris­tea Ther­a­peu­tics (Air-iss-tay-uh) is a clin­i­cal-stage im­munol­o­gy fo­cused drug de­vel­op­ment com­pany de­vel­op­ing nov­el ther­a­pies to treat se­ri­ous in­flam­ma­to­ry dis­eas­es. The Aris­tea team is lev­er­ag­ing its broad in­dus­try ex­per­tise and proven suc­cess in drug de­vel­op­ment to form syn­er­gis­tic part­n­er­ships and build a pipe­line of nov­el drugs. Aris­tea is head­quar­tered in San Die­go, CA. [more in­for­ma­tion]
Op­er­a­tor of an ar­ti­fi­cial in­tel­li­gence-based biotech­nol­o­gy com­pany in­tend­ed to help in­vent new po­ten­tial medicines for more than 50 dis­ease tar­gets. The com­pany's tech­nol­o­gy helps in drug hit dis­cov­ery, bind­ing affini­ty pre­dic­tion and toxic­i­ty de­tec­tion, en­abling sci­en­tists to dis­cov­er small molecules for the treat­ment and in­vesti­ga­tion of hu­man dis­eas­es. [more in­for­ma­tion]
Austhera Biosciences
Un­lock­ing the FULL promise of poor­ly ab­sorbed drugs and cre­at­ing nov­el NCEs for on­col­o­gy and rare dis­ease, de­liv­er­ing op­ti­mal ther­a­peu­tic ben­e­fit to pa­tients by max­i­miz­ing drug ex­po­sure. 4 Clin­i­cal Stage Prod­ucts; 1 Pre­clin­i­cal. PLAT­FORM for longer term growth with rights to dis­cov­er & de­vel­op un­tapped, in­sol­u­ble NCE prod­ucts. [more in­for­ma­tion]
Bio­Th­eryX is a clin­i­cal-stage bio­phar­ma­ceu­ti­cal com­pany fo­cused on res­tor­ing pro­tein home­os­ta­sis, in­clud­ing pro­tein degra­da­tion and mo­d­u­la­tion, and mul­ti-ki­nase in­hi­bi­tion to de­vel­op treat­ments in­tend­ed to ex­tend and im­prove the qual­i­ty-of-life of pa­tients with life-threat­en­ing dis­eas­es. [more in­for­ma­tion]
Caribou Biosciences
Cari­bou is a lead­ing com­pany in CRIS­PR genome edit­ing found­ed by pi­oneers of CRIS­PR bi­ol­o­gy. The com­pany is de­vel­op­ing an in­ter­nal pipe­line of off-the-shelf CAR-T cell ther­a­pies, other gene-edit­ed na­t­u­ral killer (NK) cell ther­a­pies, and en­gi­neered gut mi­crobes. In­ves­tors in­clude: An­ter­ra Cap­i­tal; Mis­sion Bay Cap­i­tal; No­var­tis [more in­for­ma­tion]
Carisma Therapeutics Inc.
- CARIS­MA Ther­a­peu­tics Inc. is a clin­i­cal stage bio­phar­ma­ceu­ti­cal com­pany de­vel­op­ing a dif­fer­en­ti­at­ed and pro­pri­e­tary cell ther­a­py plat­form fo­cused on en­gi­neered macrophages, cells that play a cru­cial role in both the in­nate and adap­tive im­mune re­sponse. CARIS­MA Ther­a­peu­tics is head­quar­tered in Philadel­phia, PA. [more in­for­ma­tion]
Cerebral Therapeutics
The com­pany's ther­a­pies uti­l­ize re­for­mu­lat­ed off-pa­tent drugs de­liv­ered to the ven­tri­cles of the brain in or­der to by­pass the blood-brain bar­ri­er, en­abling its clients to re­ceive a re­li­able ap­proach of treat­ing neu­ro­log­i­cal dis­eas­es for which oral in­fused medicines are not able to achieve ad­e­qu­ate con­trol. [more in­for­ma­tion]
Clerio Vision, Inc.
Nov­el oph­thalmic tech­nol­o­gy to treat re­frac­tive er­ror ad­dress­ing mul­ti-bil­lion mar­kets in con­tact lens­es (pres­by­opia) and corneal vi­sion cor­rec­tion (non sur­g­i­cal fla­p­less las­er so­lu­tion). Based on No­bel Prize win­n­ing fem­to-se­cond las­er tech­nol­o­gy de­vel­oped by Bausch & Lomb and the Uni­ver­si­ty of Roch­ester. [more in­for­ma­tion]
Crescendo Biologics
Cres­cen­do Bi­o­log­ics is a clin­i­cal stage com­pany de­vel­op­ing T cell en­hanc­ing ther­a­peu­tics. Cres­cen­do’s lead pro­gramme, CB307, is a CD137 (4-1BB) x PS­MA bis­pe­cif­ic. CB307’s unique for­mat de­liv­ers tu­mour-spe­cif­ic killing, while avoid­ing sys­temic toxic­i­ty, and can be ap­plied to a broad range of PS­MA-pos­i­tive can­cer in­di­ca­tions. It is de­signed to cause the pro­lif­er­a­tion of tu­mour-spe­cif­ic T cells, cre­at­ing a safe, broad, longer-last­ing an­ti-tu­mour re­sponse and will be in the clin­ic in ear­ly 2021. [more in­for­ma­tion]
DTx Pharma
De­vel­op­er of an RNA-based ther­a­peu­tics de­signed to aid in per­so­n­al­ized treat­ment across most ther­a­peu­tic ar­eas. The com­pany's tech­nol­o­gy en­ables ef­fi­cient de­liv­ery of nu­cle­ic acid drugs to tis­sues through­out the body, en­abling health­care providers to de­liv­er oli­gos in vi­vo at ther­a­peu­ti­cal­ly rel­e­vant dos­es that work in many cell types in­clud­ing neu­rons, en­dothe­lial and T cells. [more in­for­ma­tion]
Elevation Oncology
Our lead can­di­date, serib­an­tumab, in­hibits tu­mor growth driv­en by NRG1 fu­sions and is cur­rent­ly be­ing clin­i­cal­ly test­ed in the Phase 2 CRE­S­TONE study for pa­tients with tu­mors of any ori­gin that have an NRG1 fu­sion. [more in­for­ma­tion]
An Or­gan-Chip is a liv­ing, mi­cro­engi­neered en­vi­ron­ment that re­cre­ates the na­t­u­ral phy­si­ol­o­gy and me­chan­i­cal forces that cells ex­pe­ri­ence within the hu­man body. [more in­for­ma­tion]
ImCheck Therapeutics
Daniel Olive (INSERM, CNRS, In­sti­tut Paoli Cal­mettes, Aix­Mar­seille Uni­ver­sit&ea­cute;), a world­wide lead­er in &gam­ma;&del­ta; T cells and BTN re­search, and from the com­mit­ment of lead­ing US and Eu­ro­pean in­ves­tors. [more in­for­ma­tion]
Impact Therapeutics Inc
Im­pact Ther­a­peu­tics is a pri­vate­ly held clin­i­cal-stage bio­phar­ma­ceu­ti­cal com­pany and ded­i­cates to the dis­cov­ery and de­vel­op­ment of tar­get­ed an­ti-can­cer ther­a­peu­tics based on syn­thet­ic lethal­i­ty. [more in­for­ma­tion]
IN8bio, Inc.
IN­8bio is cur­rent­ly con­duct­ing two in­vesti­ga­tor-ini­ti­at­ed Phase 1 clin­i­cal trials for both of its lead gam­ma-del­ta T cell prod­uct can­di­dates: INB-200 for the treat­ment of new­ly di­ag­nosed glioblas­to­ma, which is a dif­fi­cult to treat brain tu­mor that pro­gress­es rapid­ly, and INB-100 for the treat­ment of pa­tients with acute leukemia un­der­go­ing he­ma­topoi­et­ic stem cell tran­s­plan­ta­tion. [more in­for­ma­tion]
IO Biotech
IO Biotech is a clin­i­cal stage biotech com­pany de­vel­op­ing dis­rup­tive im­mune ther­a­pies for the treat­ment of can­cer. The pipe­line of first-in-class im­mune mo­d­u­lat­ing an­ti-can­cer ther­a­pies is de­vel­oped by a unique tech­nol­o­gy plat­form, T-win®, en­abling the ac­ti­va­tion of T cells that are spe­cif­ic for im­mune-sup­pres­sive molecules. [more in­for­ma­tion]
ISA Pharmaceuticals BV
is an im­munother­a­py com­pany de­vel­op­ing ra­tio­n­al­ly de­signed, ful­ly syn­thet­ic im­munother­a­peu­tics against can­cer and per­sis­tent vi­ral in­fec­tions. The Com­pany has built a pro­pri­e­tary im­munother­a­py plat­form based on the Syn­thet­ic Long Pep­tide (SLP®) con­cept and AM­PLI­VANT®tech­nol­o­gy. [more in­for­ma­tion]
The com­pany lead prod­uct, DSP107, is a CD47-41BB tar­get­ing com­pound that si­mul­ta­ne­ous­ly tar­get can­cer cells, weak­en their in­nate de­fens­es and ac­ti­vate an ef­fec­tive, lo­cal re­sponse of both in­nate (by block­ing ‘Don’t eat me’ sig­nals) and adap­tive im­mu­ni­ty (by pro­vid­ing co-sti­m­u­la­tion sig­nal to T and NK cells). [more in­for­ma­tion]
Kineta Inc.
Kine­ta (Pri­vate) - whol­ly owned pre­clin­i­cal an­ti-VIS­TA (in­nate im­mune tar­get) anti­body re­pro­grams the tu­mor mi­croen­vi­ron­ment and is dif­fer­en­ti­at­ed from other im­munother­a­pies by block­ing sup­pres­sive cells in cold tu­mors. $360M+ deal with Ge­nen­tech for KCP506, Ph1 non-opi­oid for chron­ic pain. [more in­for­ma­tion]
Kriya Therapeutics
The com­pany us­es al­go­rith­mic tools, scal­able in­fras­truc­ture, and pro­pri­e­tary tech­nol­o­gy to op­ti­mize the ef­fi­ca­cy and dura­bil­i­ty of our gene ther­a­pies, there­by en­abling health­care in­sti­tu­tions to pro­vide trans­for­ma­tive new treat­ments for high­ly pre­va­lent and se­vere chron­ic dis­eas­es. [more in­for­ma­tion]
Maxwell Biosciences
The com­pany's viru­ci­dal drugs mim­ic na­t­u­ral an­timi­cro­bial pep­tides and de­stroy a broad range of virus­es di­rect­ly, ir­re­v­ersi­b­ly and per­ma­nent­ly in­ac­ti­vat­ing the virus it­self. Maxwell drug can­di­dates have di­rect viru­ci­dal ac­tion against SARS-CoV-2, the COVID-19 virus. [more in­for­ma­tion]
MiNa Therapeutics
De­vel­op­er of ther­a­peu­tic medicines de­signed to har­ness gene ac­ti­va­tion mech­anisms through small ac­ti­vat­ing RNA. The com­pany's tech­nol­o­gy and clin­i­cal know-how trans­form the ther­a­py land­s­cape of can­cer and other se­vere dis­eas­es, en­abling doc­tors and physi­cians to cure can­cer and other se­vere dis­eas­es and de­vel­op new medicines that re­s­tore nor­mal func­tion to pa­tients' cells. [more in­for­ma­tion]
Minoryx Therapeutics
Oral PPARg ag­on­ist, MIN-102, in Piv­o­tal Ph 2/3 for X-linked ALD and Ph 2 Frie­drich’s Ataxia; da­ta for both ex­pect­ed by end of 2020. VC in­ves­tors in­clude Kur­ma, Ysios, Fund+, Roche, Id­in­vest, etc [more in­for­ma­tion]
Nocion Therapeutics
The com­pany’s mis­sion is to safe­ly alle­vi­ate suf­fer­ing for mil­lions of pa­tients with con­di­tions aris­ing from ac­ti­vat­ed sen­so­ry neu­rons. [more in­for­ma­tion]
Notch Therapeutics
Notch’s tech­nol­o­gy plat­form us­es ge­net­i­cal­ly tailored stem cells as a re­ne­w­able source for cre­at­ing al­lo­gene­ic T cell ther­a­pies that ex­pand treat­ment op­tions and has the po­ten­tial to de­liv­er safer, con­sis­tent­ly man­u­fac­tured and more cost-ef­fec­tive cell im­munother­a­pies to pa­tients. [more in­for­ma­tion]
Nouscom AG
Nous­com is a next-gen­er­a­tion im­munother­a­py com­pany de­vel­op­ing ge­net­ic neoanti­gen vaccines and on­co­lyt­ic virus­es for pre­ven­tion and treat­ment of can­cer. The com­pany has of­fices in Basel and Rome. [more in­for­ma­tion]
Numab Therapeutics
We are writ­ing the next chapter in can­cer im­munother­a­py by cre­at­ing mul­ti-spe­cif­ic anti­bodies that en­able the pur­suit of nov­el ther­a­peu­tic strate­gies. With our pro­pri­e­tary MATCH™ tech­nol­o­gy plat­form we are fu­el­ing a new wave of mul­ti-spe­cif­ic drug can­di­dates en­gi­neered with ver­satil­i­ty and de­vel­o­pa­bil­i­ty in mind. [more in­for­ma­tion]
Omega Therapeutics
About Ome­ga Ther­a­peu­tics Ome­ga Ther­a­peu­tics is a pri­vate­ly held, de­vel­op­ment-stage biotech­nol­o­gy com­pany pi­oneer­ing the field of epige­nom­ic pro­gram­ming to pre­cise­ly reg­u­late and con­trol the hu­man genome to treat and cure dis­ease. [more in­for­ma­tion]
OncXerna Therapeutics
On­cX­er­na Ther­a­peu­tics of­fers a unique ap­proach to pre­ci­sion on­col­o­gy medicine based on a deep un­der­s­tand­ing of a pa­tient’s solid tu­mor mi­croen­vi­ron­ment and “dom­i­nant bi­ol­o­gy” at the RNA lev­el. [more in­for­ma­tion]
SAB Biotherapeutics
Provider of a new class of im­munother­a­pies in­tend­ed to keep pace with the emer­gence, mu­ta­tion, and di­ver­si­ty of the dis­ease. The com­pany's im­munother­a­pies help in pro­duc­ing hu­man po­ly­clo­n­al anti­bodies for a broad ar­ray of patho­gens, en­abling pa­tients to de­crease the risk of sea­so­n­al in­fluen­za, type 1 di­a­betes, and can­cers. [more in­for­ma­tion]
Sapience Therapeutics
Th­ese tar­gets are con­sid­ered un­drug­gable be­cause they are PPIs that re­side in­side of the cell, mak­ing them dif­fi­cult to treat with small molecule drugs such as che­mother­a­pies (which are in­ca­pable of dis­rupt­ing PPIs) or bi­o­log­ic-based drugs such as mon­o­clo­n­al anti­bodies (which are too big to en­ter the cell). [more in­for­ma­tion]
Secarna Pharmaceuticals GmbH
Se­car­na's unique­ly ef­fi­cient LNA­plus™ dis­cov­ery pro­cess is fu­eled by their pro­pri­e­tary and stream­lined Oli­go­fy­er™ bioin­for­mat­ics sys­tems large in-house cell li­brary and own in vit­ro screen­ing as­says. [more in­for­ma­tion]
sterna biologicals
By tar­get­ing tran­scrip­tion fac­tors that play a cen­tral role in reg­u­lat­ing Th1- and Th2-driv­en in­flam­ma­to­ry mech­anisms, the Com­pany’s pro­pri­e­tary DNAzyme-based drug can­di­dates can in­ter­vene with up­stream in­flam­ma­to­ry pro­cess­es to ad­dress re­lat­ed dis­eas­es more ef­fec­tive­ly. Ster­na cur­rent­ly has four pro­grams in phase 2 de­vel­op­ment. [more in­for­ma­tion]
Tarveda Therapeutics
is dis­cov­er­ing and de­vel­op­ing a new class of po­tent and se­lec­tive mi­nia­ture drug con­ju­gates (Pen­tarins®) for the treat­ment of pa­tients with a wide range of solid tu­mors. PEN-221 is a mi­nia­ture drug con­ju­gate in clin­i­cal eval­u­a­tion for the treat­ment of pa­tients with so­ma­to­s­tatin re­cep­tor 2 (SSTR2) ex­press­ing neu­roen­docrine, small cell lung and other solid tu­mors. [more in­for­ma­tion]
Tempest Therapeutics
Tem­pest Ther­a­peu­tics is a de­vel­op­men­t‐s­tage biotech­nol­o­gy com­pany ad­vanc­ing small molecules that mo­d­u­late an­ti‐­tu­mor im­mu­ni­ty path­ways. The com­pany has a bal­anced and deep pipe­line con­sist­ing of first‐in‐­class and po­ten­tial best‐in‐­class small molecule ther­a­peu­tics that mo­d­u­late dist­inct im­mune re­sponse path­ways rel­e­vant to mount­ing an ef­fec­tive an­ti‐­tu­mor re­sponse. [more in­for­ma­tion]
Triplet Therapeutics
Tri­plet is pur­su­ing a trans­for­ma­tive ap­proach to de­vel­op treat­ments for re­peat ex­pan­sion di­s­or­ders, a group of more than 40 known ge­net­ic dis­eas­es as­so­ci­at­ed with ex­pand­ed DNA nu­cleotide re­peats in­clud­ing Hunt­ing­ton’s dis­ease, my­o­ton­ic dys­tro­phy and vari­ous spino­cere­bel­lar ataxias. [more in­for­ma­tion]
Triumvira Immunologics
The com­pany's pro­pri­e­tary tech­nol­o­gy re­cruits the en­tire na­t­u­ral T-cell re­cep­tor and func­tions in­de­pen­dent of the Ma­jor His­to­com­pat­i­bil­i­ty Com­plex (MHC), po­ten­tial­ly al­low­ing for the de­vel­op­ment of bet­ter ther­a­pies for a broad­er range of pa­tients with solid or liquid ma­lig­nan­cies and with dis­eas­es other than can­cer, there­by pro­vid­ing med­i­cal prac­ti­tion­ers and pa­tients with new hope to deal with life-threat­en­ing dis­eas­es. [more in­for­ma­tion]
Vedanta Biosciences
De­vel­op­ing an in­no­va­tive class of ther­a­pies that mo­d­u­late path­ways of in­ter­ac­tion be­tween the hu­man mi­cro­biome and the host im­mune sys­tem. Ve­dan­ta Bio­s­ciences was co-found­ed by PureTech and a group of world renowned ex­perts in im­munol­o­gy and mi­cro­bi­ol­o­gy. [more in­for­ma­tion]
Vestaron Corporation
Ves­taron has earned glob­al recog­ni­tion for its work, in­clud­ing the inau­gu­ral 2015 Ber­nard Blum Award for nov­el bio­con­trol so­lu­tions, a 2020 THRIVE Top 50 Growth-Stage hon­oree, and the presti­gious Green Chem­istry Chal­lenge Award from the U.S. En­vi­ron­men­tal Pro­tec­tion Agen­cy and the Amer­i­can Chem­i­cal So­ci­e­ty Green Chem­istry In­sti­tute in 2020. [more in­for­ma­tion]